Medtronic, a leading medical device company, reported strong fiscal 2026 growth with $36.36 billion in revenue and a 49th consecutive year of dividend increases, yielding about 3.52%. Its diversified portfolio in cardiovascular, neuroscience, medical surgical, and diabetes devices provides stability against market cycles, supported by non-discretionary demand for life-saving products. The company’s cash flow supports dividends and buybacks, making it a reliable choice for investors seeking steady income and long-term growth. Despite some margin pressures, Medtronic’s defensive nature and attractive valuation make it suitable for retirees focusing on reinvested dividends and multi-decade holding.
Last week, six stocks announced dividend increases, with W. R. Berkley leading by raising its dividend 11.1% and declaring a 50¢ special dividend. Medtronic offers good value trading 9% below fair value but has modest dividend growth of 1.4%. Essenti...
Medtronic has finalized its $550 million acquisition of Scientia Vascular, a company specializing in advanced guidewires and catheters for treating complex neurovascular conditions. This deal strengthens Medtronic's neurovascular product lineup, aimi...
